Clinical Trials Logo

Scleroderma, Localized clinical trials

View clinical trials related to Scleroderma, Localized.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03679845 Withdrawn - Clinical trials for Morphea, Plaque Form

Study to Assess Sarilumab in Halting Progression of Morphea

Start date: September 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

An open-label single center trial studying the efficacy and safety of sarilumab on morphea patients.

NCT ID: NCT03270722 Withdrawn - Dysphagia Clinical Trials

Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

FLIP topography has been FDA cleared to evaluate a variety of esophageal conditions, but has never been evaluated in patients with scleroderma. The investigators hope to evaluate this technology in patients who have scleroderma and various esophageal symptoms, and compare to non-scleroderma patients.

NCT ID: NCT02328625 Withdrawn - Scleroderma Clinical Trials

Scleroderma Treatment With Celution Processed ADRCs Registry

STAR
Start date: April 2015
Phase: N/A
Study type: Observational [Patient Registry]

This registry study will assess the safety and performance of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand scleroderma.

NCT ID: NCT00230373 Withdrawn - Morphea Clinical Trials

Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study

Start date: November 2005
Phase: Phase 3
Study type: Interventional

Localized scleroderma or morphea is a fibrotic disease, imiquimod induces cytokines which inhibit fibrotic activity . We propose that topical imiquimod 5% cream is efficacious and safe in treating plaque-type morphea. Twenty adults will be enrolled for a pilot study. A screening and baseline clinic visit will be required for each patient enrolled in the study. Each visit will involve completing a medical history, skin examination, digital pictures, histologic examination if the patient consents and an ultrasonographic score. One morphea plaque will be treated with topical imiquimod 5% cream, and another morphea lesion with vehicle cream. Patients will be asked about side effects (local and systemic). Patients will be followed up in the clinic at 3, 6 and 9 months of therapy, and 3 months following end of treatment period (month 12).